SEC Filing Timeline
10-QMay 11, 2026
Quarterly report
8-KMay 11, 2026
Earnings release · Items 2.02,9.01
8-KApr 30, 2026
Material agreement · Items 1.01,2.02,9.01
DEFA14AApr 30, 2026
Additional proxy
DEF 14AApr 30, 2026
Proxy statement
424B5Apr 29, 2026
Prospectus / offering
424B5Apr 27, 2026
Prospectus / offering
8-KApr 27, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KApr 10, 2026
Charter/bylaws amendment · Items 5.03,9.01
424B5Mar 02, 2026
Prospectus / offering
8-KMar 02, 2026
Material agreement · Items 1.01,7.01,8.01,9.01
10-KFeb 26, 2026
Annual report
8-KFeb 26, 2026
Earnings release · Items 2.02,9.01
8-KJan 27, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
8-KJan 09, 2026
Reg FD disclosure · Items 7.01,8.01,9.01
Recent News (Finnhub)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update
High Growth Tech Stocks To Watch In US June 2026
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Present…
Intellia Therapeutics To Highlight Data From Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema In Late-Br…
Intellia Therapeutics Announces That Data From The Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema Will…
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?